A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms

Next Previous
Trial Profile

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Insulin degludec/liraglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms DUAL VI; DUAL VI-Easy Titration
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 Sep 2016 Primary endpoint (Change from baseline in HbA1c) has been met, according to results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
    • 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top